Prescribing information



Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1

Aimovig offers convenient administration every four weeks, with no loading dose1


After proper training, Aimovig can be self-administered at home by subcutaneous injection using an auto-injector or a pre-filled syringe.1


Icon of a calendar.

Aimovig can be administered as a 70 mg or 140 mg dose every 4 weeks1

Icon of a an autoinjector pen.

A 70 mg dose is administered as one 70 mg single-use, pre-filled pen. A 140 mg dose is administered as either one 140 mg single-use pen or two 70 mg single-use pens, one after the other1

Icon of a no entry sign representing no loading dose.

No loading dose1

Icon of a medicine jar with a capsule by the side.

No effect on exposure to co-administered medical products expected1

  • No interaction with oral contraceptives (ethinyl estradiol/norgestimate) or sumatriptan was observed in the studies with health volunteers1

Icon of a hand in a circle.

No contraindications other than hypersensitivity to the active substance or to any of the excipients of Aimovig1

Image of the 70 mg dose Aimovig autoinjector pen.
Image of the 140 mg dose Aimovig autoinjector pen.

Things you need to know about the Aimovig autoinjector pen2


  • Injecting Aimovig takes about 15 seconds
  • The needle is hidden inside the safety guard
  • It must be stored in the refrigerator (at 2–8°C) in the original carton to protect it from light
  • Aimovig pens must not be shaken or frozen
  • Once out of the refrigerator, it should be kept at room temperature (up to 25°C) in the original carton, and it must be used within 7 days
  • Throw it away if it has been at room temperature for more than 7 days
  • Leave the pen at room temperature for at least 30 minutes before injecting

Preview image. Your guide to Aimovig.

Your guide to Aimovig

A guide for patients prescribed Aimovig to provide them with important information about what Aimovig is, who it is for, how it works and what to expect during treatment.



Aimovig injection training video

Watch this injection video for guidance on how to administer Aimovig.



  1. Aimovig® (erenumab) Summary of Product Characteristics.
  2. Aimovig® (erenumab) Package leaflet: Information for the user.
Rate this content: 
Average: 4 (1 vote)
UK | August 2023 | 287587

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]